share_log

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $240

Moomoo 24/7 ·  Apr 11 08:49

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $270 to $240.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment